FrancophonIA/ELRC3.0 huggingface dataset:
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Estonian: Kui soovite inimravimite komitee soovituste aluse kohta lisateavet, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa avaliku hindamisaruande osa).
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Nimvastid has been shown to have comparable quality and to be bioequivalent to Exelon.
Estonian: Inimravimite komitee otsustas, et vastavalt Euroopa Liidu nõuetele on Nimvastidi võrdväärne kvaliteet ja bioekvivalentsus ravimiga Exelon tõendatud.
English: By blocking these enzymes, Nimvastid allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.
Estonian: Nende ensüümide blokeerimisega võimaldab Nimvastid atsetüülkoliini sisaldusel ajus tõusta, mis aitab vähendada Alzheimeri dementsuse ja Parkinsoni tõvega kaasneva dementsuse sümptomeid.
English: Because Nimvastid is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Estonian: Kuna Nimvastid on geneeriline ravim ja võrdlusravimiga bioekvivalentne, loetakse selle kasulikkust ja sellega kaasnevaid riske samasugusteks kui võrdlusravimil.
English: Because Nimvastid is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine (this means that the two medicines produce the same levels of the active substance in the body).
Estonian: Et Nimvastid on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Nimvastidi bioekvivalentsust võrdlusravimiga (mõlemad ravimid tekitavad organismis sama toimeainesisalduse).
English: It is also used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Estonian: Ravimit kasutatakse ka kerge kuni mõõdukalt raskekujulise dementsuse raviks Parkinsoni tõvega patsientidel.
English: Why has Nimvastid been approved?
Estonian: Miks Nimvastid heaks kiideti?
English: The capsules should be swallowed whole.
Estonian: Kapslid tuleb alla neelata tervetena.
English: Nimvastid is a medicine that contains the active substance rivastigmine.
Estonian: Nimvastid on ravim, mis sisaldab toimeainena rivastigmiini.
English: Nimvastid is a ‘generic medicine'.
Estonian: Nimvastid on geneeriline ravim.
English: Therefore, the CHMP's view was that, as for Exelon, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Exeloni puhul, ületab ravimist saadav kasu ilmnenud riskid.
English: This means that Nimvastid is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon.
Estonian: See tähendab, et Nimvastid on sarnane võrdlusravimiga Exerol, millel juba on Euroopa Liidus müügiluba.
English: The full EPAR for Nimvastid can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Nimvastidi kohta leiate siit.
English: How is Nimvastid used?
Estonian: Kuidas Nimvastidi kasutatakse?
English: Nimvastid should be given twice a day, with morning and evening meals.
Estonian: Nimvastidi manustatakse kaks korda ööpäevas, hommiku- ja õhtusöögi ajal.
English: The active substance in Nimvastid, rivastigmine, is an antidementia medicine.
Estonian: Nimvastidis toimeainena sisalduv rivastigmiin on dementsuseravim.
English: Orodispersible means that the tablets dissolve in the mouth.
Estonian: Suus dispergeeruvad tabletid lahustuvad suus.
English: Treatment with Nimvastid should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease.
Estonian: Ravi Nimvastidiga võib alustada üksnes Alzheimeri tõve või Parkinsoni tõvega kaasneva dementsuse diagnoosimises ja ravis kogenud arst ning see peab toimuma tema järelevalve all.
English: In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain,
Estonian: Alzheimeri dementsuse või Parkinsoni tõvega kaasneva dementsusega patsientidel hävivad ajus teatud närvirakud, mille tulemusena väheneb neurotransmitteri (keemiline aine, mis vahendab signaale närvirakkude vahel) atsetüülkoliini sisaldus.
English: What is Nimvastid used for?
Estonian: Milleks Nimvastidi kasutatakse?
English: How does Nimvastid work?
Estonian: Kuidas Nimvastid toimib?
English: How has Nimvastid been studied?
Estonian: Kuidas Nimvastidi uuriti?
English: This summary was last updated in 09-2011.
Estonian: Kokkuvõtte viimane uuendus: 09-2011.
English: However, the time taken for the disease to get worse after treatment was the same in both groups (about 10
Estonian: Samas oli pärast ravi haiguse süvenemiseni kulunud aeg mõlemas rühmas ühesugune (ligikaudu 10 kuud).
English: The full EPAR for Zevalin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zevalini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Zevalin is used in the following groups of patients:
Estonian: Zevalini kasutatakse järgmistel patsiendirühmadel:
English: Zevalin must be given as a slow infusion lasting 10 minutes.
Estonian: Zevalini peab manustama 10 minutit kestva aeglase infusioonina.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zevalin on 16 January 2004.
Estonian: Euroopa Komisjon andis Zevalini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. jaanuaril
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 22 May 2008.
Estonian: Et ettevõte esitas vajaliku lisateabe, tühistati müügiloa erandkorras väljastatus 22. mail 2008.
English: Zevalin is not used directly, but it must be radiolabelled before use.
Estonian: Zevalini ei kasutata vahetult, vaid see tuleb enne kasutamist radiomärgistada.
English: This is followed, seven to nine days later, by a second infusion of rituximab and an injection of radiolabelled Zevalin.
Estonian: Sellele järgneb 7-9 päeva hiljem teine rituksimaabi infusioon ning radiomärgistatud Zevalini süstimine.
English: In both studies, the main measure of effectiveness was the number of patients whose disease responded partially or completely to treatment.
Estonian: Mõlemas uuringus oli efektiivsuse põhinäitaja osalise või täieliku ravivastusega patsientide arv.
English: The Committee recommended that Zevalin be given marketing authorisation.
Estonian: Komitee soovitas anda Zevalini müügiloa.
English: The doctor who prescribes it must ensure that the risks linked to the exposure to the radioactivity are lower than the risks from the disease itself.
Estonian: Ravimit määrav arst peab eelnevalt veenduma, et radioaktiivse ühendiga kokkupuutest tulenevad riskid on väiksemad kui haigusest endast tingitud riskid.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zevalin.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Other information about Zevalin
Estonian: Muu teave Zevalini kohta
English: For more information about treatment with Zevalin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zevaliniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Radiolabelled Zevalin is radioactive and its use may carry a risk of cancer and hereditary defects.
Estonian: Radiomärgistatud Zevalin on radioaktiivne ning selle kasutamine võib põhjustada vähiriski või pärilike väärarengute tekke riski.
English: Zevalin was originally authorised under ‘exceptional circumstances' because it had not been possible to obtain complete information about Zevalin.
Estonian: Zevalini müügiluba anti esialgu erandkorras, sest ravimi kohta ei olnud võimalik saada täielikku teavet.
English: This is a summary of the European public assessment report (EPAR) for Zevalin.
Estonian: Käesolev dokument on ravimi Zevalin Euroopa avaliku hindamisaruande kokkuvõte.
English: However, there were too few patients who had received rituximab as part of their induction treatment to determine whether there would be a benefit of using Zevalin as consolidation treatment in these patients.
Estonian: Samas oli induktsiooniravi osana rituksimaabi saanud patsiente liiga vähe, et nende tulemuste põhjal otsustada, kas Zevalini kasutamine konsolideerimisravina on sellistele patsientidele kasulik.
English: The most common side effects with Zevalin (seen in more than 1 patient in 10) are anaemia (low red blood cell counts), leucocytopenia and neutropenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), asthenia (weakness), pyrexia (fever), rigors (stiffness) and nausea (feeling sick).
Estonian: Zevalini kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on aneemia (punaliblede vähesus), leukotsütopeenia ja neutropeenia (valgeliblede vähesus), trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus), asteenia (nõrkus), palavik, külmavärinad (kangestus) ja iiveldus.
English: In the additional study, radiolabelled Zevalin brought about a response in about half of the patients.
Estonian: Lisauuringus tekitas radiomärgistatud Zevalin ravivastuse ligikaudu pooltel patsientidel.
English: Radiolabelling is a technique where a substance is tagged (labelled) with a radioactive compound.
Estonian: Radiomärgistamine on meetod, kus aine märgistatakse radioaktiivse ühendiga.
English: Zevalin must not be used in patients who are pregnant or breast feeding.
Estonian: Zevalini ei rohi kasutada rasedad või imetavad patsiendid.
English: When Zevalin was used as consolidation therapy, patients survived for longer without their disease getting worse than when they received no further treatment.
Estonian: Kui Zevalini kasutati konsolideeriva ravina, elasid patsiendid haiguse halvenemiseta kauem kui lisaravita patsiendid.
English: Zevalin should not be used in people who may be hypersensitive (allergic) to ibritumomab, yttrium chloride, mouse proteins or any of the other ingredients.
Estonian: Zevalini ei tohi kasutada patsiendid, kes võivad olla ibritumomaabi, ütriumkloriidi, hiire valkude või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The study compared patients who received Zevalin and patients who received no additional treatment.
Estonian: Uuringus võrreldi Zevalini saavaid patsiente nendega, kes lisaravi ei saanud.
English: For the full list of all side effects reported with Zevalin, see the package leaflet.
Estonian: Zevalini kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Radiolabelled Zevalin treatment should only be handled and given by someone who is authorised to use radioactive medicines.
Estonian: Radiomärgistatud Zevalini tohib käidelda ja manustada vaid radiomärgistatud ravimite käitlusõigusega isik.
English: The CHMP decided that Zevalin's benefits are greater than its risks as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma and for the treatment of adult patients with rituximab relapsed or refractory CD20-positive follicular B cell non Hodgkin's lymphoma.
Estonian: Inimravimite komitee otsustas, et Zevalini kasulikkus on suurem kui sellega kaasnevad riskid, kui ravimit kasutatakse konsolideerivaks raviks pärast remissiooni tekkimist varem ravimata follikulaarse lümfoomiga patsientidel, ja kui Zevalini kasutatakse koos rituksimaabiga neil täiskasvanud patsientidel, kellel on relapsidega või refraktoorne CD20-positiivsete follikulaarsete B-rakkudega mitte-Hodgkini lümfoom.
English: Once the antibody has bound to the antigen, the radiation can act locally and destroy the lymphoma B cells.
Estonian: Kui antikeha on antigeeniga seondunud, saab kiirgus toimida paikselt ning hävitada lümfoomi B-rakke.
English: • patients who have gone into remission (reduction in the number of cancerous cells) after their first
Estonian: • patsiendid, kellel pärast lümfoomivastase ravi alustamist (sissejuhatav keemiaravi) esines remissioon (vähirakkude hulga vähenemine).
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found in certain cells in the body.
Estonian: Zevalini toimeaine ibritumomaab on monoklonaalne antikeha (teatud valk), mis tunneb ära teatud antigeeni (organismi teatud rakkudel leiduva spetsiifilise struktuuri) ja seondub sellega.
English: Ibritumomab has been designed to target an antigen, CD20, which is present on the surface of all B lymphocytes.
Estonian: Ibritumomaab on ette nähtud seonduma antigeeniga CD20, mida leidub kõigi B-lümfotsüütide pinnal.
English: What is the risk associated with Zevalin?
Estonian: Mis riskid Zevaliniga kaasnevad?
English: This enables Zevalin to deliver radiation more specifically to the cancerous B-cells.
Estonian: See võimaldab Zevalinil kiiritada ainult kantserogeenseid B-rakke.
English: Why has Zevalin been approved?
Estonian: Miks Zevalin heaks kiideti?
English: The main measure of effectiveness was the length of time the patients survived without their disease getting worse.
Estonian: Efektiivsuse põhinäitaja oli haiguse halvenemiseni kulunud aeg.
English: What is Zevalin?
Estonian: Mis on Zevalin?
English: Zevalin has also been studied in a total of 306 patients with non Hodgkin's lymphoma who were not responding to other treatments or whose disease had come back after previous treatment.
Estonian: Zevalini uuriti ka nendel mitte-Hodgkini lümfoomiga patsientidel (kokku 306 patsienti), kellel ei tekkinud muude raviskeemide suhtes ravivastust või kelle haigus oli pärast eelmist ravikuuri taastunud.
English: When Zevalin is radiolabelled, the radioactive element yttrium 90 (90Y) is attached to ibritumomab.
Estonian: Kui Zevalin on radiomärgistatud, kinnitub radioaktiivne element ütrium90 (90Y) ibritumomaabi külge.
English: This is a cancer of the lymph tissue (part of the immune system) that affects a type of white blood cell called B lymphocytes, or B cells.
Estonian: See haigus on lümfikoe (immuunsüsteemi osa) vähk, mis kahjustab teatud valgeliblesid B-lümfotsüüte ehk B-rakke.
English: Before treatment with radiolabelled Zevalin, the patients must first receive an infusion of rituximab (at a dose lower than would be used for treatment) to clear B cells from their circulation, leaving the cancerous B cells in the lymph tissue.
Estonian: Enne ravi radiomärgistatud Zevaliniga tuleb esmalt tilgutada patsiendi verre rituksimaabi (raviannusest väiksemas annuses), et eemaldada tema vereringest B-rakud, jättes kantserogeensed B-rakud lümfikoesse.
English: For consolidation therapy, Zevalin has been studied in one main study involving 414 patients who had achieved a partial or complete remission during induction treatment for non Hodgkin's lymphoma.
Estonian: Zevalini kasutamist konsolideerimisravis uuriti ühes põhiuuringus, milles osales 414 patsienti, kellel oli mitte-Hodgkini lümfoomi alustamisravi kestel tekkinud osaline või täielik remissioon.
English: Patients receiving radiolabelled Zevalin survived for an average of 37 months until their disease got worse, compared with 14 months in those who did not receive any further treatment.
Estonian: Patsientidel, kellele manustati radiomärgistatud Zevalini, kulus haiguse halvenemiseni keskmiselt 37 kuud, samas kui lisaravita patsientidel kulus 14 kuud.
English: EPAR summary for the public ibritumomab tiuxetan
Estonian: Kokkuvõte üldsusele ibritumomaabtiuksetaan
English: The main study compared the effectiveness of Zevalin with that of rituximab in 143 patients.
Estonian: Põhiuuringus võrreldi 143 patsiendil Zevalini toimet rituksimaabi toimega.
English: The dose of Zevalin is calculated to give the appropriate amount of radioactivity for the patient's condition, based on the blood cell count.
Estonian: Zevalini annus arvutatakse vererakkude sisalduse põhjal, et patsiendi saadav radioaktiivsusannus oleks vastavuses tema seisundiga.
English: When the radiolabelled medicine is injected into the patient, the monoclonal antibody carries the radioactivity to the target CD20 antigen on the B cells.
Estonian: Radiomärgistatud ravimi süstimisel patsiendile kannab monoklonaalne antikeha radioaktiivsuse Brakkudel oleva CD20 antigeenini.
English: What benefit has Zevalin shown during the studies?
Estonian: Milles seisneb uuringute põhjal Zevalini kasulikkus?
English: ‘consolidation therapy' to improve the remission; patients in whom rituximab (another treatment for non Hodgkin's lymphoma) is no longer effective or whose disease has come back after rituximab treatment.
Estonian: • patsiendid, kellele rituksimaab (samuti mitte-Hodgkini lümfoomi ravim) enam ei toimi või kelle haigus on pärast rituksimaabi ravi taastunud.
English: • The radiolabelled medicine is used to treat adult patients with follicular B cell non Hodgkin's lymphoma.
Estonian: Radiomärgistatud Zevalini kasutatakse follikulaarse B-rakulise mitte-Hodgkini lümfoomi raviks täiskasvanud patsientidel.
English: How is Zevalin used?
Estonian: Kuidas Zevalini kasutatakse?
English: How does Zevalin work?
Estonian: Kuidas Zevalin toimib?
English: Zevalin is radiolabelled by mixing it with a solution of radioactive yttrium (90Y) chloride.
Estonian: Zevalini radiomärgistamiseks segatakse see radioaktiivse ütriumkloriidi (90Y) lahusega.
English: What is Zevalin used for?
Estonian: Milleks Zevalini kasutatakse?
English: How has Zevalin been studied?
Estonian: Kuidas Zevalini uuriti?
English: Zevalin is a kit for the preparation of a ‘radiolabelled' infusion (drip into a vein) of the active substance ibritumomab tiuxetan.
Estonian: Zevalin on komplekt radiomärgistusega toimeaine ibritumomaabtiuksetaani infusiooni (veeni tilgutatava lahuse) ettevalmistamiseks.
English: In an additional study, 57 patients with follicular lymphoma who had been previously treated and were not responding to rituximab received Zevalin.
Estonian: Lisauuringus manustati Zevalini 57-le follikulaarse lümfoomiga patsiendile, kellel rituksimaabi suhtes ravivastust ei tekkinud.
English: In patients who were not responding to other treatments or whose disease had come back after previous treatment, Zevalin was more effective than rituximab: 80% of the patients receiving radiolabelled Zevalin responded, compared with 56% of the patients receiving rituximab.
Estonian: Patsientidel, kellel muude raviskeemide korral ei olnud tekkinud ravivastust või kelle haigusseisund oli eelmise raviskeemi järel taastunud, oli Zevalin efektiivsem kui rituksimaab.
English: The capsules should be swallowed whole with water.
Estonian: Kapslid tuleb neelata alla tervelt koos veega.
English: It is used to treat adults with the following conditions:
Estonian: Seda kasutatakse järgmiste haigusseisundite ravimiseks täiskasvanutel:
English: • generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).
Estonian: • generaliseerunud ärevushäire (pikaaegne ärevus või närvilisus argiasjade pärast).
English: The medicine can only be obtained with a prescription and is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg).
Estonian: Pregabalin Pfizer on retseptiravim ja seda turustatakse kapslitena (25, 50, 75, 100, 150, 200, 225 ja 300 mg).
English: This medicine is the same as Lyrica, which is already authorised in the European Union (EU).
Estonian: See ravim on sarnane Lyricaga, millel juba on Euroopa Liidus müügiluba.
English: Stopping treatment with Pregabalin Pfizer should also be done gradually, over at least a week.
Estonian: Ka ravi lõpetamine Pregabalin Pfizeriga peaks toimuma järk-järgult, vähemalt nädala jooksul.
English: The full EPAR and risk management plan summary for Pregabalin Pfizer can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Pregabalin Pfizeri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Patients who have kidney problems need to take lower doses.
Estonian: Neeruprobleemidega patsiendid vajavad väiksemaid annuseid.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Pfizer on 10 April 2014.
Estonian: Euroopa Komisjon andis Pregabalin Pfizeri müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 10. aprillil 2014.
English: A risk management plan has been developed to ensure that Pregabalin Pfizer is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Pregabalin Pfizeri võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Pregabalin Pfizer?
Estonian: Mis meetmed võetakse, et tagada Pregabalin Pfizeri ohutu ja efektiivne kasutamine?
English: The company that makes Lyrica has agreed that its scientific data can be used for Pregabalin Pfizer (‘informed consent').
Estonian: Lyrica tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Pregabalin Pfizeri toetuseks (teabel põhinev nõusolek).
English: The CHMP decided that Pregabalin Pfizer's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Pregabalin Pfizeri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Pregabalin Pfizer is a medicine that contains the active substance pregabalin.
Estonian: Pregabalin Pfizer on ravim, mis sisaldab toimeainena pregabaliini.
English: • neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury;
Estonian: • neuropaatiline valu (närvikahjustusest põhjustatud valu), sealhulgas perifeerne neuropaatiline valu diabeedi või vöötohatisega (herpes zoster) patsientidel ja tsentraalne neuropaatiline valu, näiteks pärast seljaaju vigastust;
English: The active substance in Pregabalin Pfizer, pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma-amino butyric acid (GABA), but has very different biological effects.
Estonian: Pregabalin Pfizeri toimeaine pregabaliin sarnaneb struktuurilt organismi looduslikule neurotransmitterile gamma-aminovõihappele (GABA), kuid on teistsuguse bioloogilise toimega.
English: Pregabalin Pfizer pregabalin
Estonian: Pregabalin Pfizer pregabaliin
English: In neuropathic pain, the benefits of Pregabalin Pfizer were evaluated for up to 12 weeks using a standard pain questionnaire.
Estonian: Neuropaatilise valu ravis hinnati Pregabalin Pfizeri kasulikkust kuni 12 nädala jooksul, kasutades valuskaala standardküsimustikku.
English: What is Pregabalin Pfizer and what is it used for?
Estonian: Mis on Pregabalin Pfizer ja milleks seda kasutatakse?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pregabalin Pfizer, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Kava alusel lisati Pregabalin Pfizeri omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The most common side effects with Pregabalin Pfizer (seen in more than 1 patient in 10) are dizziness and somnolence (sleepiness).
Estonian: Pregabalin Pfizeri kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10-st) on peapööritus ja unisus.